Ipants (Evaluation 1.7). Adverse events This outcome was di icult to summarise as a result of poor and inconsistent reporting, and we TGF-beta/Smad list didn’t meta-analyse any data. However, there usually do not seem to be any really serious issues concerning adverse e ects of KGF. We’ve got tabulated relevant information and facts in Further Table 1. Quantity of days in hospitalAdults receiving bone marrow/stem cell transplantation a er conditioning therapy for haematological cancersThere was insu icient evidence from 3 studies, two at low (Henke 2011; Le 2011), and 1 at unclear danger of bias (SphK2 site Brizel 2008), to figure out no matter whether or not KGF reduces the risk of getting unscheduled radiotherapy breaks of 5 or far more days: RR 1.01, 95 CI 0.65 to 1.59; 473 participants (Evaluation 1.4). There was insu icient proof, in the same two research at low risk of bias, to figure out whether or not KGF reduces the risk of getting chemotherapy delays/discontinuations: RR 0.96, 95 CI 0.62 to 1.47; 374 participants (Evaluation 1.5). Oral painAdults receiving bone marrow/stem cell transplantation a er conditioning therapy for haematological cancersThere was insu icient evidence, from 1 study at low danger of bias (Blijlevens 2013), to identify whether or not or not KGF reduces the imply variety of days in hospital: MD 0.00, 95 CI -1.64 to 1.64; 281 participants (Analysis 1.9). Number of days of treatment with opioid analgesicsAdults getting bone marrow/stem cell transplantation a er conditioning therapy for haematological cancersThere was insu icient proof, from one particular study at low threat of bias (Freytes 2004), to identify no matter whether or not KGF reduces the mean worst discomfort experienced on a 0 (no pain) to 10 (worst discomfort) scale: imply di erence (MD) -0.85, 95 CI -3.00 to 1.30; 42 participants (Evaluation 1.six).Adults receiving radiotherapy towards the head and neck with cisplatinThere was some imprecise evidence, from two studies at low threat of bias (Blijlevens 2013; Freytes 2004), that KGF could lead to a reduction inside the imply number of days of treatment with opioid analgesics: MD -1.41, 95 CI -3.33 to 0.51; 323 participants (Evaluation 1.ten). The typical e ect is around 1.five days reduction, but the confidence interval is compatible with each a reduction of virtually three.five days and a rise of half a day. No research assessed the outcomes ‘quality of life’ and ‘number of days unable to take medicine orally’. Keratinocyte development element (KGF) dose comparisons There was some inconsistent evidence from which no conclusions can be drawn concerning di erent dosages of KGF (Evaluation 2.1; Analysis 2.2; Evaluation two.3; Analysis 2.four; Evaluation 2.5; Evaluation 2.6; Evaluation 2.7; Evaluation 2.8). Keratinocyte growth factor (KGF) versus chlorhexidine A single study, at higher threat of bias and analysing 90 youngsters getting mixed chemotherapy alone for acute lymphoblastic leukaemia (Gholizadeh 2016), compared KGF by IV infusion with chlorhexidine mouthwash. There was weak proof (due to risk of bias and low sample size) that KGF performs much better than chlorhexidine in reducing the danger of any amount of oral mucositis (RR 0.67, 95 CI 0.54 to 0.85; Evaluation 3.1), moderate to severe oral mucositis (RR 0.12, 95 CI 0.05 to 0.28; Analysis 3.two), and severe oral mucositis (RR 0.01, 95 CI 0.00 to 0.19; Analysis 3.three).There was some evidence, from two research at low threat of bias (Henke 2011; Le 2011), that KGF may result in a reduction within the mean discomfort score on a 0 (no pain) to four (worst discomfort) scale: MD -0.12, 95 CI -0.27 to 0.02; 374 participants (Analysis.